Analysis of Financial Track Record
Value Creation |
|---|
| Mar'11 | Mar'12 | Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Capital Employed | 8.2% | 9.55% | 12.29% | 14.94% | 10.79% | 12.1% | 11.24% | 3.17% | 3.42% | 3.37% |
| Growth Parameters |
|---|
| 9 yrs | 5 yrs | 3 yrs | 1 yr | |
|---|---|---|---|---|
| Net Sales | 7.5% | 10.2% | 9.6% | 14.4% |
| Adjusted EPS | 8.7% | -6.7% | -37.3% | -15.5% |
| Book Value per Share | 19.6 | 25.1 | 28.3 | 1.4 |
| Share Price | 39.4% | 14.8% | 16.8% | 187.6% |
| Key Financial Parameter |
|---|
Management X-Ray
Shareholding Pattern
| Entity | Percentage Holding |
|---|---|
| Promoters | 36.25% |
| Institutions | 23.02% |
| Non-Institutions | 40.73% |
Promoter's Holding & Share Pledging
| Pledged * | 4.32 | 4.32 | 4.34 | 4.34 | 4.35 | 4.35 | 4.31 | 4.30 | 4.30 | 4.30 |
FAQs
The 5-year analysis of Neuland Laboratories Ltd's performance infers:
Neuland Laboratories Ltd earnings have declined by -6.7%, whereas share price has appreciated 14.8% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.We analysed the performance of Neuland Laboratories Ltd share prices over the last 10 years. Here is what we found out:
Neuland Laboratories Ltd share price has appreciated 29.4% annually over the past ten years. About Company
Named after Father Nieuwland of Notre dame, Neuland Laboratories was incorporated in 1984 by Dr. D. R. Rao for the manufacture of Salbutamol Sulphate, with mere 40 employees.
It has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.
Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with
Named after Father Nieuwland of Notre dame, Neuland Laboratories was incorporated in 1984 by Dr. D. R. Rao for the manufacture of Salbutamol Sulphate, with mere 40 employees.
It has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.
Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery. Neuland is a quality conscious, research driven, reliable source of active pharmaceutical ingredients.
Operating from India for over two decades, Neuland is the preferred source for the Pharmaceutical Industry across the globe, with strengths in Research based Chemistry and Manufacturing.
The Company has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery.
Neuland has two world-class API manufacturing facilities close to the city of Hyderabad, capable in handling complex and hazardous reactions. Safety aspects have been given utmost significance may it be plant installation, equipment, systems and personnel to ensure smooth productivity. Dedicated team of manufacturing with incorporation of latest production techniques guarantees delivery of latest intermediate and product to our customers across the globe.
Product range of the company includes:
- Anti -Asthmatics
- Fluoroquinolones
- Cardiovascular
- CNS
- Corticosteroids
- Anti-Ulcerant
- Anti-Fungal
- Anti-Parkinsons
- Anti-Alzheimers
Achievements/ recognition:
- Received a string of regulatory approvals from USFDA & EDQM for its major products (e.g., Ciprofloxacin HCl, Salbutamol Sulphate) USFDA systems inspection for its pashamylaram Facility (Unit-II) in the year 1999
- USFDA systems inspection for its Bonthapally (Unit-I) bringing both facilities under full cGMP compliance in 2004
- Received cGMP clearance for both facilities from TGA, Australia in 2004.
- Certificate of suitability for product itraconazole in 2006.
